Consequently, the identification of reliable molecular biomarkers, such as PSA and PSMA in men, allowing an early detection and reliable prognosis of canine prostatic cancer would be of significant value for future development and evaluation of therapeutic strategies as well as the assessment of treatment response [2]. Here, FOLH1 is linked to prostate carcinoma.